Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Gilead Sciences, Inc (NASDAQ: GILD) closed the day trading at $119.36 down -1.51% from the previous closing price of $121.19. In other words, the price has decreased by -$1.51 from its previous closing price. On the day, 5.44 million shares were traded. GILD stock price reached its highest trading level at $122.24 during the session, while it also had its lowest trading level at $119.02.
Ratios:
For a better understanding of GILD, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.14 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.16. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.45. In the meantime, Its Debt-to-Equity ratio is 1.16 whereas as Long-Term Debt/Eq ratio is at 1.03.
On November 13, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $140.
Daiwa Securities Upgraded its Neutral to Outperform on August 19, 2025, while the target price for the stock was maintained at $128.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 28 ’25 when Bluestone Jeffrey sold 5,000 shares for $125.08 per share. The transaction valued at 625,400 led to the insider holds 8,920 shares of the business.
Kramer Kelly A. sold 2,806 shares of GILD for $356,671 on Nov 26 ’25. The Director now owns 1,339 shares after completing the transaction at $127.11 per share. On Nov 28 ’25, another insider, Kramer Kelly A., who serves as the Director of the company, sold 2,805 shares for $127.10 each. As a result, the insider received 356,516 and left with 1,339 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GILD now has a Market Capitalization of 148102709248 and an Enterprise Value of 166762184704. As of this moment, Gilead’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.49, and their Forward P/E ratio for the next fiscal year is 13.70. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.52. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.10 while its Price-to-Book (P/B) ratio in mrq is 6.88. Its current Enterprise Value per Revenue stands at 5.733 whereas that against EBITDA is 11.797.
Stock Price History:
The Beta on a monthly basis for GILD is 0.35, which has changed by 0.31186402 over the last 52 weeks, in comparison to a change of 0.12529528 over the same period for the S&P500. Over the past 52 weeks, GILD has reached a high of $128.70, while it has fallen to a 52-week low of $88.57. The 50-Day Moving Average of the stock is -1.32%, while the 200-Day Moving Average is calculated to be 5.58%.
Shares Statistics:
Over the past 3-months, GILD traded about 7.29M shares per day on average, while over the past 10 days, GILD traded about 6593010 shares per day. A total of 1.24B shares are outstanding, with a floating share count of 1.24B. Insiders hold about 0.21% of the company’s shares, while institutions hold 88.33% stake in the company. Shares short for GILD as of 1763078400 were 17007031 with a Short Ratio of 2.33, compared to 1760486400 on 15804496. Therefore, it implies a Short% of Shares Outstanding of 17007031 and a Short% of Float of 1.37.
Dividends & Splits
GILD’s forward annual dividend rate is 3.14, up from 3.14 a year ago. Against a Trailing Annual Dividend Yield of 0.02590973. The stock’s 5-year Average Dividend Yield is 3.82. The current Payout Ratio is 805.23% for GILD, which recently paid a dividend on 2025-09-15 with an ex-dividend date of 2025-12-15. Stock splits for the company last occurred on 2013-01-28 when the company split stock in a 2:1 ratio.
Earnings Estimates
Gilead Sciences, Inc (GILD) is presently subject to a detailed evaluation by 20.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $2.05, with high estimates of $2.19 and low estimates of $1.85.
Analysts are recommending an EPS of between $8.43 and $8.05 for the fiscal current year, implying an average EPS of $8.17. EPS for the following year is $8.72, with 28.0 analysts recommending between $9.5 and $6.38.
Revenue Estimates
19 analysts predict $7.65B in revenue for. The current quarter. It ranges from a high estimate of $8.2B to a low estimate of $6.95B. As of. The current estimate, Gilead Sciences, Inc’s year-ago sales were $7.57BFor the next quarter, 19 analysts are estimating revenue of $7.04B. There is a high estimate of $7.25B for the next quarter, whereas the lowest estimate is $6.9B.
A total of 25 analysts have provided revenue estimates for GILD’s current fiscal year. The highest revenue estimate was $29.72B, while the lowest revenue estimate was $28.6B, resulting in an average revenue estimate of $29.21B. In the same quarter a year ago, actual revenue was $28.75BBased on 27 analysts’ estimates, the company’s revenue will be $30.08B in the next fiscal year. The high estimate is $31.25B and the low estimate is $28.72B.
